{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:46:28Z","timestamp":1785743188654,"version":"3.56.0"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>In the phase I inMMyCAR study of the in vivo chimeric antigen receptor (CAR) T-cell therapy KLN-1010, all 18 patients with multiple myeloma responded. None of the evaluable patients had minimal residual disease 1 month after treatment, suggesting that the therapy could prove clinically useful.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nw2026-0067","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:46:51Z","timestamp":1780994811000},"page":"OF1-OF1","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<i>In Vivo<\/i>\n                    CAR T-Cell Therapy Spurs 100% ORR in Phase I"],"prefix":"10.1158","volume":"16","member":"1086","published-online":{"date-parts":[[2026,6,9]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-NW2026-0067\/785753\/In-Vivo-CAR-T-Cell-Therapy-Spurs-100-ORR-in-Phase","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/OF1\/787107\/In-Vivo-CAR-T-Cell-Therapy-Spurs-100-ORR-in-Phase","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/OF1\/787107\/In-Vivo-CAR-T-Cell-Therapy-Spurs-100-ORR-in-Phase","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:14:26Z","timestamp":1785741266000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/OF1\/787107\/In-Vivo-CAR-T-Cell-Therapy-Spurs-100-ORR-in-Phase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":0,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,6,9]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nw2026-0067","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}